Newly approved vaccines for respiratory syncytial virus (RSV) may reduce severe disease, similar to how COVID-19 vaccines lessen the severity of SARS-CoV-2 infections, according to new research funded by the Centers for Disease Control and Prevention (CDC).
The study published April 4 in JAMA Network Open found that during the 16 months preceding approval of the first adult RSV vaccines, individuals with RSV experienced disease severity similar to unvaccinated patients hospitalized with COVID-19 or influenza—but were “substantially more severe” than vaccinated patients hospitalized with COVID-19 or influenza.
